Editorial: Obesity, metabolic phenotypes and COVID-19

Editorial: Obesity, metabolic phenotypes and COVID-19

Bibliographic Details
Main Authors: Arao, K. (Author), Belanger, M.J (Author), Hill, M.A (Author), Mantzoros, C.S (Author), Sanoudou, D. (Author)
Format: Article
Language:English
Published: W.B. Saunders 2022
Subjects:
adipose tissue
Adipose Tissue
age
Age Factors
alcohol consumption
amfebutamone plus naltrexone
body weight loss
clinical outcome
comorbidity
Comorbidity
complication
control strategy
coronavirus disease 2019
COVID-19
diet therapy
disease severity
Editorial
high risk population
human
Humans
immunomodulation
inflammation
liraglutide
Metabolic Diseases
metabolic disorder
metabolic phenotype
metabolism
mortality
Mortality
NAFLD
nutrition
obesity
Obesity
Obesity phenotypes
obesity stigma
Outcomes
pandemic
Pandemics
pathology
pathophysiology
patient acuity
Patient Acuity
pharmacological procedures
phenotype
Phenotype
phentermine plus topiramate
physical activity
physiology
prognosis
Prognosis
renin angiotensin aldosterone system
respiratory system
Respiratory System
SARS-CoV-2
semaglutide
Severe acute respiratory syndrome coronavirus 2
sodium glucose cotransporter 2 inhibitor
tetrahydrolipstatin
thrombosis
Treatment
virology
Online Access:View Fulltext in Publisher
LEADER 02604nam a2200949Ia 4500
001 10-1016-j-metabol-2021-155121
008 220420s2022 CNT 000 0 und d
020 |a 00260495 (ISSN) 
245 1 0 |a Editorial: Obesity, metabolic phenotypes and COVID-19 
260 0 |b W.B. Saunders  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1016/j.metabol.2021.155121 
650 0 4 |a adipose tissue 
650 0 4 |a Adipose Tissue 
650 0 4 |a age 
650 0 4 |a Age Factors 
650 0 4 |a alcohol consumption 
650 0 4 |a amfebutamone plus naltrexone 
650 0 4 |a body weight loss 
650 0 4 |a clinical outcome 
650 0 4 |a comorbidity 
650 0 4 |a Comorbidity 
650 0 4 |a complication 
650 0 4 |a control strategy 
650 0 4 |a coronavirus disease 2019 
650 0 4 |a COVID-19 
650 0 4 |a COVID-19 
650 0 4 |a diet therapy 
650 0 4 |a disease severity 
650 0 4 |a Editorial 
650 0 4 |a high risk population 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a immunomodulation 
650 0 4 |a inflammation 
650 0 4 |a liraglutide 
650 0 4 |a Metabolic Diseases 
650 0 4 |a metabolic disorder 
650 0 4 |a metabolic disorder 
650 0 4 |a metabolic phenotype 
650 0 4 |a metabolism 
650 0 4 |a mortality 
650 0 4 |a Mortality 
650 0 4 |a NAFLD 
650 0 4 |a nutrition 
650 0 4 |a obesity 
650 0 4 |a obesity 
650 0 4 |a Obesity 
650 0 4 |a Obesity 
650 0 4 |a Obesity phenotypes 
650 0 4 |a obesity stigma 
650 0 4 |a Outcomes 
650 0 4 |a pandemic 
650 0 4 |a Pandemics 
650 0 4 |a pathology 
650 0 4 |a pathophysiology 
650 0 4 |a patient acuity 
650 0 4 |a Patient Acuity 
650 0 4 |a pharmacological procedures 
650 0 4 |a phenotype 
650 0 4 |a Phenotype 
650 0 4 |a phentermine plus topiramate 
650 0 4 |a physical activity 
650 0 4 |a physiology 
650 0 4 |a prognosis 
650 0 4 |a Prognosis 
650 0 4 |a renin angiotensin aldosterone system 
650 0 4 |a respiratory system 
650 0 4 |a Respiratory System 
650 0 4 |a SARS-CoV-2 
650 0 4 |a semaglutide 
650 0 4 |a Severe acute respiratory syndrome coronavirus 2 
650 0 4 |a sodium glucose cotransporter 2 inhibitor 
650 0 4 |a tetrahydrolipstatin 
650 0 4 |a thrombosis 
650 0 4 |a Treatment 
650 0 4 |a virology 
700 1 0 |a Arao, K.  |e author 
700 1 0 |a Belanger, M.J.  |e author 
700 1 0 |a Hill, M.A.  |e author 
700 1 0 |a Mantzoros, C.S.  |e author 
700 1 0 |a Sanoudou, D.  |e author 
773 |t Metabolism: Clinical and Experimental 

Similar Items